Injectable oxyTOCIN solution recalled nationwide after sterility assurance questioned
Central Admixture Pharmacy Services is recalling oxyTOCIN 20 units in 0.9% sodium chloride injectable solution nationwide after an FDA inspection raised questions about the products' sterility assurance.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a risk-of-harm product (sterile injectable medication) where no injuries or illnesses have been reported. The hazard is theoretical—a failure of sterility assurance in injectable drugs. Per the rubric, risk-of-harm products with no reported injury qualify for a severity of 3 (High).
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling oxyTOCIN 20 units added to 0.9% sodium chloride solution in 1,000 mL bags, distributed nationwide in the United States. The recall affects approximately 5,544 bags.
During an FDA inspection, questions were raised about whether the manufacturer could assure the sterility of the product. For injectable medications, which must remain sterile, this assurance is critical to safe use.
Healthcare facilities and providers should verify whether they have any of the affected lots in inventory using the lot numbers and expiration dates provided in the FDA recall notice. Affected products should be removed from use immediately.
The recalled product
- Product
- oxyTOCIN 20 units added to 0.9% sodium chloride 1,000 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 72185-6043-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Sterile Injectable
- Affected units
- 5,544
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # 37-883938
- Exp 05/02/2023
- 37-884910
- 37-884915
- Exp 05/07/2023
- 37-886041
- Exp 05/10/2023
- 37-887515
- 37-887520
- Exp 05/16/2023
- 37-888318
- Exp 05/21/2023
- 37-888847
- Exp 05/22/2023
- 37-890535
- Exp 05/29/2023
- 37-890957
- Exp 05/30/2023
- 37-891566
- 37-891568
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 108 recalled by Central Admixture Pharmacy Services, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 108 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services, Inc.
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · sterility assurance failure
See all →- HighDELFLEX Peritoneal Dialysis Solution bags recalled for sterility risk
FDA (Drugs) · 2026-05-13
- SevereTirzepatide/Cyanocobalamin Injectable Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2025-07-02
- HighOmnicell IVX Station Reconstitution Transfer Sets Recall
FDA (Devices) · 2025-04-16
- HighCompounded Fentanyl and Bupivacaine Epidural Injections Recalled for Sterility Assurance
FDA (Drugs) · 2025-04-02
- HighHYDROmorphone Injectable Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2024-04-03